Clinical trial NCT00391534: EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy
Official title: Safety and Efficacy of a Novel Modified Release Formulation of Oxcarbazepine (OXC MR) vs an Immediate Release Oxcarbazepine (OXC IR) Product in Patients With Partial Epilepsy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Partial Epilepsy
Keywords: Epilepsy
oxcarbazepine
Lead sponsor: Desitin Arzneimittel GmbH
Sponsor class: INDUSTRY
Collaborators: name: FGK Clinical Research GmbH
First posted: 2006-10-24
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is intended to investigate the safety and efficacy of a novel formulation of oxcarbazepine that is released more slowly than the current formulation. The study medication will be used as a treatment against partial epilepsy.

Detailed description: This is a multi-centre, randomized, open-label, flexible-titration, controlled, parallel-group study to investigate the safety and efficacy of a novel modified release formulation of oxcarbazepine (OXC MR) compared to an immediate release oxcarbazepine (OXC IR) product in patients with partial epilepsy. Adult patients of both gender, aged at least 18 years with refractory partial epilepsy, with or without secondary generalisation receiving a stable background treatment with daily dosages of exactly 900 or 1200 or 1500 mg Oxcarbazepine will be enrolled. Concomitant medication consisting of maximal 2 additional AEDs (vagus nerve stimulator included) is allowed and must be kept stable throughout the study. Patients, who agree to participate, will first sign and date the informed consent and undergo an evaluation at screening visit to determine eligibility. Those patients who qualify will be enrolled in the study, assigned a patient ID, and will enter the 4-week baseline period. Each patient will receive a seizure diary to record the number of seizures during the baseline period. For Visit 1 the patient will return to the clinic and complete all baseline procedures. Patients who have met the entry criteria will be randomised. The two treatment groups consist of 50 patients each, one group to be treated with OXC MR b.i.d. and the other to be treated with OXC IR b.i.d. in a 1:1 randomization. Following assignment to one of both treatment groups the patient will enter the dose-titration phase. From Visit 1 (Study Day 1) a total daily dose of 1200 mg /1500 mg /1800 mg oxcarbazepine will be given to the randomised patients. From Day 6 the dosage will be titrated to a maximum total daily dose of 2700 mg in steps of 300 mg every 6th day. Patients who experienced intolerable adverse events could reduce their daily dose by 150 mg on the 2nd day of up-titration for the remainder of the treatment period. In case the reduced dosage will also not be tolerated, in a second step the dosage can be reduced by further 150 mg OXC. The maximal tolerated dose achieved on up-titration will be maintained up to the final visit (Study Day 26).

Eligibility criteria: Inclusion Criteria:

* Female and male patients with minimal age of 18 years on the date of the first study visit.
* Stable treatment with Oxcarbazepine treatment (Timox® /Trileptal®), dosage: exactly 900 mg or exactly 1200 mg or exactly 1500 mg for at least 1 month prior to screening.
* \>= 2 partial onset seizures with or without secondary generalisation refractory to existing AED therapy within the baseline period.
* Weight between \>= 50 kg and \< 100 kg.
* for females with child-bearing potential: negative pregnancy rest and highly effective form of birth control (females using hormonal contraceptives should use a different or additional means of birth control, e.g. IUD, abstinence, vasectomized partner, double barriere methods with or without oral contraceptives)
* Stable regimen of \<= 2 concomitant AEDs (vagus nerve stimulator included) during the baseline period; lamotrigine dose may be adjusted at baseline.
* Ethnic origin: Caucasian.
* Subjects capable of complying with the study stipulations.
* Patients who have provided written informed consent to participate in this study.

Exclusion Criteria:

* Epilepsy secondary to progressive metabolic disease, malignant neoplasm, substance abuse, or active infection.
* Status epilepticus at any time during the baseline period.
* Lennox-Gastaut syndrome.
* Generalized epilepsy as primary diagnosis.
* Severe cardiac, pulmonary, haematological, hepatic, renal or neoplastic pathology.
* Acute medical conditions and/or conditions that could interfere with the absorption, metabolism or excretion of oxcarbazepine.
* History of clinically relevant psychiatric illness and/or drug abuse, drug addiction or alcoholism within the last 2 years.
* Treatment with psychotropic drugs, anticholinergic drugs, anti-parkinson medication, α1-antagonists, α2-antagonists, carbamazepine, topiramate, felbamate, vigabatrin. Stable treatment with selective serotonin-reuptake-inhibitor (SSRI) having been given for at least 4 weeks prior to screening as supportive treatment of partial epilepsy can be accepted.
* Intake of sodium lowering medication, e.g. diuretics and non-steroidal anti- inflammatory drugs. Occasional and short-term intake of non-steroidal anti- inflammatory drugs on demand (Ibuprofen, Paracetamol, ASS, Diclofenac and others) is allowed.
* Hypersensitivity towards oxcarbazepine or chemically related drugs.
* Low sodium serum levels (\< 128 mmol/L). Sodium serum levels ≥ 126 and \< 128 mmol/L can be accepted for inclusion, if these levels have been stable for at least 3 months.
* Symptomatic hyponatremia.
* Pregnancy or breast feeding.
* Participation in drug trials during 3 months preceding the study.

Primary outcomes:
measure: Maintenance dosage where dose up-titration has to be discontinued due to AEs
timeFrame: whenever criterion is met
Secondary outcomes:
measure: Number of seizures during the trial
timeFrame: Visit 1, Visit 2, Final Visit and each unscheduled visit
measure: OXC and MHD plasma levels obtained from 6 patients per centre
timeFrame: Visit 1, Visit 2, Final Visit and each unscheduled visit
measure: Adverse event profile Plus (AEP) questionnaire-score
timeFrame: at each patient contact
measure: EpiTrack
timeFrame: Visit 1, Visit 2, Final Visit and each unscheduled visit
measure: Vital Signs and ECG
timeFrame: Visit 1, Visit 2, Final Visit and each unscheduled visit
measure: Laboratory parameters (hematology, serum chemistry, coagulation, urinalysis)
timeFrame: Visit 1, Visit 2, Final Visit
Other outcomes:
Locations:
city: Bergisch Gladbach
country: Germany
city: Bonn
country: Germany
city: Erlangen
country: Germany
city: Freiburg
country: Germany
city: Göttingen
country: Germany
city: Kehl-Kork
country: Germany
Study officials:
affiliation: Klinik für Epileptologie, Universität Bonn, Bonn, Germany
name: Christian E. Elger, Prof. MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Desitin Arzneimittel GmbH
name: Martina Wangemann, Dr.
role: STUDY_DIRECTOR
References: